| Journal | Psychopharmacology |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Oxandrolone, a synthetic anabolic androgenic steroid, is widely used for its muscle-building effects but has been associated with anxiety and mood disturbances. We hypothesized that chronic oxandrolone exposure disrupts inhibitory, excitatory, monoaminergic, and neuromodulatory signaling within the amygdala, a brain region critical for emotional regulation, and that metformin may attenuate these effects due to its reported neuroprotective properties. Adult male rats were treated daily with oxandrolone for 14 days, with or without metformin co-administration. Anxiety-like behavior was assessed, followed by targeted neurochemical analysis of the dissected amygdala. Levels of GABAergic, glutamatergic, cholinergic, and monoaminergic neurotransmitters, along with key endocannabinoids and the neuropeptide oxytocin, were quantified using liquid chromatography mass spectrometry to comprehensively evaluate systems implicated in anxiety and affective regulation. Oxandrolone treatment induced pro
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
